ADT + bevacizumab as first-line treatment of recurrent prostate cancer

Data from a small, randomized, Phase II, clinical trial have suggested a possible role for bevacizumab (Avastin) in the treatment of men with recurrent prostate cancer along with androgen deprivation therapy (ADT). … READ MORE …

Avastin does NOT extend survival of patients with HRPC

The pharmaceutical company Roche announced this morning that the combination of bevacizumab (Avastin) with docetaxel and prednisone does not extend the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. … READ MORE …